R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.52 CNY -4.55%
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Pre-Tax Income
ÂĄ182.5m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Pre-Tax Income
ÂĄ9.9B
CAGR 3-Years
26%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Pre-Tax Income
ÂĄ2.1B
CAGR 3-Years
10%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
3%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Pre-Tax Income
ÂĄ1.3B
CAGR 3-Years
-25%
CAGR 5-Years
8%
CAGR 10-Years
24%
W
WuXi XDC Cayman Inc
HKEX:2268
Pre-Tax Income
ÂĄ359.6m
CAGR 3-Years
123%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 17%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Pre-Tax Income?
Pre-Tax Income
182.5m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Pre-Tax Income amounts to 182.5m CNY.

What is R&G PharmaStudies Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
24%

Over the last year, the Pre-Tax Income growth was 42%. The average annual Pre-Tax Income growth rates for R&G PharmaStudies Co Ltd have been 24% over the past three years .

Back to Top